Breaking News Instant updates and real-time market news.

CELG

Celgene

$99.64

1.14 (1.16%)

10:47
10/18/16
10/18
10:47
10/18/16
10:47

Piper calls Celgene's GED-0301 'interesting but risky'

Piper Jaffray analyst Joshua Schimmer says that while the Phase II study of Celgene's GED-0301 for Crohn's Disease is "perhaps encouraging," a larger, placebo controlled trial is needed to have confidence in the program. GED-0301 remains "interesting but risky," Schimmer adds, while pointing out the drug is not in his model at this time. He reiterates an Overweight rating on Celgene.

  • 18

    Oct

  • 27

    Oct

  • 06

    Nov

CELG Celgene
$99.64

1.14 (1.16%)

10/14/16
ADAM
10/14/16
NO CHANGE
Target $156
ADAM
Buy
Celgene pipeline broader and stronger than ever, says Canaccord
Canaccord analyst John Newman said Celgene's pipeline is broader and stronger than at any point in its history.He reiterated his Buy rating based on his confidence in the commercial potential for GED-0301 for Crohn's disease, ozanimod in both ulcerative colitis and multiple sclerosis, and continued growth for Otezla. Newman reiterated his $156 price target on Celgene shares.
10/17/16
WELS
10/17/16
NO CHANGE
WELS
Celgene data better than expected, says Wells Fargo
After Celgene announced detailed results from a phase 1b study of oral mogersen in moderate-to severe Crohn's Disease, Wells Fargo says that the results "are better than expected" and leave the company's drug "favorably" positioned relative to approved biologics. The firm says that Celgene's drug "could be positioned as the first highly effective oral for Crohn's Disease," and it keeps an Outperform rating on the stock.
10/17/16
LEER
10/17/16
NO CHANGE
LEER
Market Perform
Celgene data suggests viable drug, says Leerink
Leerink analyst Geoffrey Porges notes that Celgene has announced top-line results from Phase 1b study of GED-301 in Crohn's Disease, and says that absent statistical analyses or a greater insight into participant performance across the study's treatment arms, or longer duration of follow-up, it is difficult to evaluate the full significance of these results. Nonetheless, the analyst believes the drug seems to have some modest efficacy which bodes positively for potential approval as a front-line agent in Crohn's Disease. He reiterates a Market Perform rating on the shares.
10/18/16
JEFF
10/18/16
NO CHANGE
JEFF
Jefferies sees 'attractive buying opportunities' in Biotech
The Jefferies Biotechnology team sees "attractive buying opportunities" amidst the pre-election weakness. While volatility will likely continue into the election, valuation multiples are near-historic lows and policy concerns, while valid, are likely overstated, the analysts tell investors in a research note. They recommend using the weakness to buy select names ahead of a potential improvement in sentiment. Jefferies likes Gilead (GILD) and Celgene (CELG) among large-caps, The Medicines Co. (MDCO), Alkermes (ALKS) and Vertex (VRTX) among mid-caps, and Alder Biopharmaceuticals (ALDR), Cempra (CEMP), Ultragenyx (RARE) and Immunomedics (IMMU) among small-caps.

TODAY'S FREE FLY STORIES

RTN

Raytheon

$155.27

-0.74 (-0.47%)

07:02
04/27/17
04/27
07:02
04/27/17
07:02
Hot Stocks
Breaking Hot Stocks news story on Raytheon »

Raytheon reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

RTN

Raytheon

$155.27

-0.74 (-0.47%)

07:02
04/27/17
04/27
07:02
04/27/17
07:02
Hot Stocks
Breaking Hot Stocks news story on Raytheon »

Raytheon reports Q1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

SIRI

Sirius XM

$5.11

-0.095 (-1.83%)

07:02
04/27/17
04/27
07:02
04/27/17
07:02
Hot Stocks
Sirius XM reports 31.6M subscribers in Q1 »

The company added 259,000…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 18

    May

PSTB

Park Sterling Bank

$12.52

0.23 (1.87%)

, SSB

South State

$91.90

1.35 (1.49%)

07:02
04/27/17
04/27
07:02
04/27/17
07:02
Hot Stocks
Park Sterling Bank, South State announce merger agreement »

South State Corporation…

PSTB

Park Sterling Bank

$12.52

0.23 (1.87%)

SSB

South State

$91.90

1.35 (1.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 15

    May

  • 25

    May

AIT

Applied Industrial Technologies

$64.10

0.95 (1.50%)

07:02
04/27/17
04/27
07:02
04/27/17
07:02
Earnings
Applied Industrial Technologies sees Q4 EPS 68c-78c, consensus 68c »

Sees Q4 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

  • 09

    May

RTN

Raytheon

$155.27

-0.74 (-0.47%)

07:02
04/27/17
04/27
07:02
04/27/17
07:02
Earnings
Raytheon reports Q1 EPS $1.73, consensus $1.61 »

Reports Q1 revenue $6B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

SIRI

Sirius XM

$5.11

-0.095 (-1.83%)

07:01
04/27/17
04/27
07:01
04/27/17
07:01
Earnings
Sirius XM reports Q1 EPS 4c, consensus 4c »

Reports Q1 revenue $1.3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 18

    May

AIT

Applied Industrial Technologies

$64.10

0.95 (1.50%)

07:01
04/27/17
04/27
07:01
04/27/17
07:01
Earnings
Applied Industrial Technologies reports Q3 EPS 75c, consensus 63c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

  • 09

    May

BMY

Bristol-Myers

$53.77

-0.17 (-0.32%)

07:00
04/27/17
04/27
07:00
04/27/17
07:00
Earnings
Bristol-Myers reports Q1 adjusted EPS 84c, consensus 74c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 03

    May

  • 06

    Jun

ANTM

Anthem

$179.03

6.57 (3.81%)

07:00
04/27/17
04/27
07:00
04/27/17
07:00
Upgrade
Anthem rating change  »

Anthem upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

SHOP

Shopify

$74.12

-2.53 (-3.30%)

07:00
04/27/17
04/27
07:00
04/27/17
07:00
Downgrade
Shopify rating change  »

Shopify downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 24

    May

I

Intelsat

$3.73

-0.08 (-2.10%)

06:59
04/27/17
04/27
06:59
04/27/17
06:59
Earnings
Intelsat backs FY17 revenue view $2.18B-$2.23B, consensus $2.19B »

Backs FY17 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

UA

Under Armour

$18.14

0.17 (0.95%)

, UAA

Under Armour

$19.71

0.18 (0.92%)

06:59
04/27/17
04/27
06:59
04/27/17
06:59
Earnings
Under Armour backs FY17 view for revenues growth of 11%-12% »

There are no changes to…

UA

Under Armour

$18.14

0.17 (0.95%)

UAA

Under Armour

$19.71

0.18 (0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

LLL

L3 Technologies

$171.76

1.3 (0.76%)

06:59
04/27/17
04/27
06:59
04/27/17
06:59
Hot Stocks
Breaking Hot Stocks news story on L3 Technologies »

L3 Technologies backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

JCI

Johnson Controls

$43.05

-0.15 (-0.35%)

06:58
04/27/17
04/27
06:58
04/27/17
06:58
Earnings
Breaking Earnings news story on Johnson Controls »

Johnson Controls narrows…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

I

Intelsat

$3.73

-0.08 (-2.10%)

06:58
04/27/17
04/27
06:58
04/27/17
06:58
Earnings
Intelsat reports Q1 EPS (29c), consensus (13c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

UA

Under Armour

$18.14

0.17 (0.95%)

, UAA

Under Armour

$19.71

0.18 (0.92%)

06:58
04/27/17
04/27
06:58
04/27/17
06:58
Earnings
Under Armour reports Q1 EPS (1c), consensus (4c) »

Reports Q1 revenue…

UA

Under Armour

$18.14

0.17 (0.95%)

UAA

Under Armour

$19.71

0.18 (0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

LLL

L3 Technologies

$171.76

1.3 (0.76%)

06:57
04/27/17
04/27
06:57
04/27/17
06:57
Earnings
L3 Technologies raises FY17 EPS view to $8.50-$8.70 from $8.40-$8.60 »

FY17 consensus $8.60.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

JCI

Johnson Controls

$43.05

-0.15 (-0.35%)

06:57
04/27/17
04/27
06:57
04/27/17
06:57
Earnings
Breaking Earnings news story on Johnson Controls »

Johnson Controls sees Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

AB

AllianceBernstein

$22.75

-0.05 (-0.22%)

06:57
04/27/17
04/27
06:57
04/27/17
06:57
Earnings
AllianceBernstein reports Q1 EPS 46c, consensus 44c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

WEX

WEX

$106.85

0.83 (0.78%)

06:57
04/27/17
04/27
06:57
04/27/17
06:57
Earnings
WEX sees Q2 adjusted EPS $1.19-$1.26, consensus $1.30 »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

JCI

Johnson Controls

$43.05

-0.15 (-0.35%)

06:56
04/27/17
04/27
06:56
04/27/17
06:56
Earnings
Johnson Controls reports Q2 adj. EPS 49c, consensus 49c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 31

    May

AZN

AstraZeneca

$30.58

0.09 (0.30%)

06:56
04/27/17
04/27
06:56
04/27/17
06:56
Earnings
AstraZeneca confirms FY17 core EPS to decline low to mid teens percentage »

Backs FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 26

    Jun

WEX

WEX

$106.85

0.83 (0.78%)

06:56
04/27/17
04/27
06:56
04/27/17
06:56
Earnings
WEX sees FY17 adjusted EPS $5.15-$5.50, consensus $5.33 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 09

    May

LLL

L3 Technologies

$171.76

1.3 (0.76%)

06:55
04/27/17
04/27
06:55
04/27/17
06:55
Hot Stocks
Breaking Hot Stocks news story on L3 Technologies »

L3 Technologies raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.